Comparison of injection site reactions and flu-like symptoms between users of peginterferon beta-1a and subcutaneous interferon beta-1a among persons with multiple sclerosis in the New York State Multiple Sclerosis Consortium

被引：0
|
作者：
Vaughn, C. [1 ,2 ,3 ]
Kavak, K. [1 ,3 ]
Bushra, A. [3 ]
Nadeem, M. [3 ]
Zakalik, K. [1 ,3 ]
Teter, B. [1 ]
Weinstock-Guttman, B. [1 ,2 ,3 ]
机构：
[1] New York State Multiple Sclerosis Consortium, Buffalo, NY USA
[2] SUNY Buffalo, Neurol, Buffalo, NY USA
[3] Jacobs MS Ctr Treatment & Res, Buffalo, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1806
引用
收藏
页码：953 / 954
页数：2
相关论文
共 50 条
  • [21] Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy
    Sandberg-Wollheim, Magnhild
    Alteri, Enrica
    Moraga, Margaretha Stam
    Kornmann, Gabrielle
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (04) : 423 - 430
  • [22] Subcutaneous Interferon beta-1a Treatment and Pregnancy Outcomes in Patients with Multiple Sclerosis
    Sandberg-Wollheim, Magnhild
    Alteri, Enrica
    Moraga, Margaretha Stam
    Kornmann, Gabrielle
    NEUROLOGY, 2010, 74 (09) : A404 - A404
  • [23] Interferon beta-1a for multiple sclerosis: old drug, new clothes
    Hartung, Hans-Peter
    LANCET NEUROLOGY, 2014, 13 (07): : 638 - 639
  • [24] Real-world outcomes in patients with relapsing forms of multiple sclerosis treated with intramuscular interferon beta-1a or peginterferon beta-1a
    Salter, A.
    Lancia, S.
    Cutter, G.
    Fox, R.
    Marrie, R. A.
    Avila, R.
    Vignos, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 187 - 187
  • [25] Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis
    Minagar, Alireza
    Alexander, J. Steven
    Schwendimann, Robert N.
    Kelley, Roger E.
    Gonzalez-Toledo, Eduardo
    Jimenez, Joaquim J.
    Mauro, Lucia
    Jy, Wenche
    Smith, Stacy J.
    ARCHIVES OF NEUROLOGY, 2008, 65 (02) : 199 - 204
  • [26] Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients
    Castelli-Haley, Jane
    Oleen-Burkey, Merry-Kay A.
    Lage, Maureen J.
    Johnson, Kenneth P.
    ADVANCES IN THERAPY, 2008, 25 (07) : 658 - 673
  • [27] Alemtuzumab versus interferon beta-1a in early multiple sclerosis
    Dennis Bourdette
    Vijayshree Yadav
    Current Neurology and Neuroscience Reports, 2009, 9 (5) : 341 - 342
  • [28] Interferon beta-1a in relapsing-remitting multiple sclerosis
    Blumhardt, L
    HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195
  • [29] PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update
    Reuss, Reinhard
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 131 - 138
  • [30] Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
    Hauser, S. L.
    Bar-Or, A.
    Comi, G.
    Giovannoni, G.
    Hartung, H. -P.
    Hemmer, B.
    Lublin, F.
    Montalban, X.
    Rammohan, K. W.
    Selmaj, K.
    Traboulsee, A.
    Wolinsky, J. S.
    Arnold, D. L.
    Klingelschmitt, G.
    Masterman, D.
    Fontoura, P.
    Belachew, S.
    Chin, P.
    Mairon, N.
    Garren, H.
    Kappos, L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 221 - 234
12345